Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.
Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.
Earns most of its income selling sartan blood-pressure ingredients and intermediates to generic drugmakers, with international buyers such as Teva and Sandoz taking much of it. It is adding contract development and manufacturing for other drug companies and its own finished tablets to lessen reliance on bulk ingredients.
Moat: narrow (regulatory licence, process know-how). European CEP and other regulatory filings plus process know-how; ingredient prices remain competitive.
Headquarters: Taizhou, China · Founded: 2003 · Employees: 4,686
Size Zhejiang Tianyu Pharmaceutical (300702.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.02B, the 2128th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.80 on 18 Nov 2026.
Performance Over six months the shares gained 1.2%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 27.2% over the last twelve months (peer median +5.9%); the operating margin is 4.0% (peer median 10.9%).
Valuation It trades at 21.4× forward earnings against a peer median of 18.3× (7th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.79B | CN¥3.04B | CN¥2.62B | CN¥2.51B | CN¥2.66B |
| Revenue growth | — | +16% | +4% | -6% | — |
| Gross profit | CN¥1.40B | CN¥1.02B | CN¥810M | CN¥889M | CN¥603M |
| EBITDA | n/a | CN¥559M | CN¥444M | CN¥453M | CN¥176M |
| Net income | CN¥69.3M | CN¥140M | CN¥55.9M | CN¥27.4M | -CN¥119M |
| Free cash flow | CN¥506M | CN¥116M | CN¥176M | -CN¥361M | -CN¥575M |
| Capital expenditure | CN¥337M | CN¥358M | CN¥169M | CN¥317M | CN¥527M |
| Total debt | CN¥2.34B | CN¥2.16B | CN¥2.37B | CN¥2.14B | CN¥1.99B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Tianyu Pharmaceutical 300702.SZ | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300702.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.0% | -6.0% | 10th highest of 21 |
| 6-month return | +1.2% | -11.5% | 7th highest of 21 |
| Distance from 52-week high | -28.8% | -32.4% | 9th highest of 21 |
| Revenue growth (TTM) | +27.2% | +5.9% | 5th highest of 19 |
| Operating margin | 4.0% | 10.9% | 6th lowest of 19 |
| Forward P/E | 21.4× | 18.3× | 7th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 4.3% | 2.5% | 7th most demanding of 14 |
| Growth delivered (Del g) | +3.5% | +7.7% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | +0.8 pp | -3.6 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | +0.5 pp | +0.1 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |